MedPath

Treatment of "Low Anterior Resection Syndrome" by Percutaneous Nerve Evaluation and Transanal Irrigation

Not Applicable
Terminated
Conditions
Rectal Cancer
Interventions
Procedure: Percutaneous nerve evaluation
Registration Number
NCT01313026
Lead Sponsor
University of Aarhus
Brief Summary

A randomised trial testing the effect of percutaneous nerve evaluation and transanal irrigation on bowel function in patients after low anterior resection for rectal cancer.

Detailed Description

Patients will undergo anal physiological assessment and will then be randomized to either treatment arm. The first 12 weeks they will be optimized in the conservative treatment of their bowel function before beginning active treatment with TAI or PNE. After 8 and 4 weeks respectively, the treatment will stop and they will have a period of 4 weeks back on optimized conservative treatment before beginning active treatment in the other active arm.

Detailed records of bowel, micturition and sexual function and QoL will be obtained at regular intervals during the entire trial fase.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
14
Inclusion Criteria
  • Low anterior resection for rectal cancer between May 2001 and May 2011
Read More
Exclusion Criteria
  • Non-radical resection
  • metastatic disease
  • Chemotherapy
  • Radiotherapy
  • Previously treated for another cancer
  • Dementia or other mental retardation/severe mental disease
  • Inability to read and understand the Danish language
  • Recurrent disease
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
PNE firstPercutaneous nerve evaluationpatients randomised to start with PNE stimulation over 4 weeks. Then the stimulator will be removed and after a wash out period of 4 weeks they will be trained in transanal irrigation
TAI firstPercutaneous nerve evaluationPatients randomised to start with transanal irrigation treatment in 8 weeks, thereafter a wash out period of 4 weeks before being implanted with a neuro stimulator
Primary Outcome Measures
NameTimeMethod
changes in LARS scorebaseline, 12, 16, 20, 24 and 28 weeks

A symptom score ranging from 0 to 42 points calculated on the basis of bowel function

Secondary Outcome Measures
NameTimeMethod
Incontinencebaseline, 12, 16, 20, 24 and 28 weeks

faecal incontinence measured by wexner score and St. Marks incontinence score

Sexual functionbaseline, 12, 16, 20, 24 and 28 weeks

self-reported sexual function measured by validated questionnaires

Patient Satisfactionbaseline, 12, 16, 20, 24 and 28 weeks

patient satisfaction measured on a VAS

Bladder functionbaseline, 12, 16, 20, 24 and 28 weeks

self-reported bladder function by validated questionnaires

Trial Locations

Locations (1)

Colorectal Surgical Department P, Aarhus University Hospital

🇩🇰

Aarhus, Denmark

© Copyright 2025. All Rights Reserved by MedPath